Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice. / Skandorff, Isabella; Ragonnaud, Emeline; Gille, Jasmin; Andersson, Anne Marie; Schrödel, Silke; Duvnjak, Lara; Turner, Louise; Thirion, Christian; Wagner, Ralf; Holst, Peter Johannes.

In: International Journal of Molecular Sciences, Vol. 24, No. 12, 9972, 2023.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Skandorff, I, Ragonnaud, E, Gille, J, Andersson, AM, Schrödel, S, Duvnjak, L, Turner, L, Thirion, C, Wagner, R & Holst, PJ 2023, 'Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice', International Journal of Molecular Sciences, vol. 24, no. 12, 9972. https://doi.org/10.3390/ijms24129972

APA

Skandorff, I., Ragonnaud, E., Gille, J., Andersson, A. M., Schrödel, S., Duvnjak, L., Turner, L., Thirion, C., Wagner, R., & Holst, P. J. (2023). Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice. International Journal of Molecular Sciences, 24(12), [9972]. https://doi.org/10.3390/ijms24129972

Vancouver

Skandorff I, Ragonnaud E, Gille J, Andersson AM, Schrödel S, Duvnjak L et al. Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice. International Journal of Molecular Sciences. 2023;24(12). 9972. https://doi.org/10.3390/ijms24129972

Author

Skandorff, Isabella ; Ragonnaud, Emeline ; Gille, Jasmin ; Andersson, Anne Marie ; Schrödel, Silke ; Duvnjak, Lara ; Turner, Louise ; Thirion, Christian ; Wagner, Ralf ; Holst, Peter Johannes. / Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice. In: International Journal of Molecular Sciences. 2023 ; Vol. 24, No. 12.

Bibtex

@article{7e508cdac32f4845896455dca4ca687d,
title = "Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice",
abstract = "Expression of human endogenous retrovirus type W (HERV-W) has been linked to cancer, making HERV-W antigens potential targets for therapeutic cancer vaccines. In a previous study, we effectively treated established tumours in mice by using adenoviral-vectored vaccines targeting the murine endogenous retrovirus envelope and group-specific antigen (Gag) of melanoma-associated retrovirus (MelARV) in combination with anti-PD-1. To break the immunological tolerance to MelARV, we mutated the immunosuppressive domain (ISD) of the MelARV envelope. However, reports on the immunogenicity of the HERV-W envelope, Syncytin-1, and its ISD are conflicting. To identify the most effective HERV-W cancer vaccine candidate, we evaluated the immunogenicity of vaccines encoding either the wild-type or mutated HERV-W envelope ISD in vitro and in vivo. Here, we show that the wild-type HERV-W vaccine generated higher activation of murine antigen-presenting cells and higher specific T-cell responses than the ISD-mutated counterpart. We also found that the wild-type HERV-W vaccine was sufficient to increase the probability of survival in mice subjected to HERV-W envelope-expressing tumours compared to a control vaccine. These findings provide the foundation for developing a therapeutic cancer vaccine targeting HERV-W-positive cancers in humans.",
keywords = "adenovirus vector, human endogenous retrovirus type W (HERV-W), immunosuppressive domain, Syncytin-1",
author = "Isabella Skandorff and Emeline Ragonnaud and Jasmin Gille and Andersson, {Anne Marie} and Silke Schr{\"o}del and Lara Duvnjak and Louise Turner and Christian Thirion and Ralf Wagner and Holst, {Peter Johannes}",
note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",
year = "2023",
doi = "10.3390/ijms24129972",
language = "English",
volume = "24",
journal = "International Journal of Molecular Sciences (Online)",
issn = "1661-6596",
publisher = "MDPI AG",
number = "12",

}

RIS

TY - JOUR

T1 - Human Ad19a/64 HERV-W Vaccines Uncover Immunosuppression Domain-Dependent T-Cell Response Differences in Inbred Mice

AU - Skandorff, Isabella

AU - Ragonnaud, Emeline

AU - Gille, Jasmin

AU - Andersson, Anne Marie

AU - Schrödel, Silke

AU - Duvnjak, Lara

AU - Turner, Louise

AU - Thirion, Christian

AU - Wagner, Ralf

AU - Holst, Peter Johannes

N1 - Publisher Copyright: © 2023 by the authors.

PY - 2023

Y1 - 2023

N2 - Expression of human endogenous retrovirus type W (HERV-W) has been linked to cancer, making HERV-W antigens potential targets for therapeutic cancer vaccines. In a previous study, we effectively treated established tumours in mice by using adenoviral-vectored vaccines targeting the murine endogenous retrovirus envelope and group-specific antigen (Gag) of melanoma-associated retrovirus (MelARV) in combination with anti-PD-1. To break the immunological tolerance to MelARV, we mutated the immunosuppressive domain (ISD) of the MelARV envelope. However, reports on the immunogenicity of the HERV-W envelope, Syncytin-1, and its ISD are conflicting. To identify the most effective HERV-W cancer vaccine candidate, we evaluated the immunogenicity of vaccines encoding either the wild-type or mutated HERV-W envelope ISD in vitro and in vivo. Here, we show that the wild-type HERV-W vaccine generated higher activation of murine antigen-presenting cells and higher specific T-cell responses than the ISD-mutated counterpart. We also found that the wild-type HERV-W vaccine was sufficient to increase the probability of survival in mice subjected to HERV-W envelope-expressing tumours compared to a control vaccine. These findings provide the foundation for developing a therapeutic cancer vaccine targeting HERV-W-positive cancers in humans.

AB - Expression of human endogenous retrovirus type W (HERV-W) has been linked to cancer, making HERV-W antigens potential targets for therapeutic cancer vaccines. In a previous study, we effectively treated established tumours in mice by using adenoviral-vectored vaccines targeting the murine endogenous retrovirus envelope and group-specific antigen (Gag) of melanoma-associated retrovirus (MelARV) in combination with anti-PD-1. To break the immunological tolerance to MelARV, we mutated the immunosuppressive domain (ISD) of the MelARV envelope. However, reports on the immunogenicity of the HERV-W envelope, Syncytin-1, and its ISD are conflicting. To identify the most effective HERV-W cancer vaccine candidate, we evaluated the immunogenicity of vaccines encoding either the wild-type or mutated HERV-W envelope ISD in vitro and in vivo. Here, we show that the wild-type HERV-W vaccine generated higher activation of murine antigen-presenting cells and higher specific T-cell responses than the ISD-mutated counterpart. We also found that the wild-type HERV-W vaccine was sufficient to increase the probability of survival in mice subjected to HERV-W envelope-expressing tumours compared to a control vaccine. These findings provide the foundation for developing a therapeutic cancer vaccine targeting HERV-W-positive cancers in humans.

KW - adenovirus vector

KW - human endogenous retrovirus type W (HERV-W)

KW - immunosuppressive domain

KW - Syncytin-1

UR - http://www.scopus.com/inward/record.url?scp=85163962357&partnerID=8YFLogxK

U2 - 10.3390/ijms24129972

DO - 10.3390/ijms24129972

M3 - Journal article

C2 - 37373123

AN - SCOPUS:85163962357

VL - 24

JO - International Journal of Molecular Sciences (Online)

JF - International Journal of Molecular Sciences (Online)

SN - 1661-6596

IS - 12

M1 - 9972

ER -

ID: 360071188